Together, we can turn groundbreaking concepts into impactful solutions.
Partnering with government, institutions, foundations, and nonprofits, we tackle pressing health challenges efficiently through the power of collaboration. Our experienced team of experts in science, medicine, engineering, and business work alongside our partners to identify and nurture high-potential health innovation projects.


Moving Ideas Forward
- Proven Processes: Streamlined methodologies that ensure efficiency and effectiveness.
- Hands-On Facilitation: Direct, personalized assistance at every step of the innovation process.
- Global Network: Access to a world-class network of experts ready to lend insights and experience.
- Customized Tools: Tailored infrastructure, tools, and resources designed to fit the needs of your project.

Our Impact
We have supported more than 1,200 innovator teams, evaluated more than 5,000 ideas, and helped develop more than a thousand health innovations. Our efforts have resulted in:
- 49% commercialization success rate.
- $2 billion in follow-on funding.
- 1000+ healthcare innovations developed.
- touching millions of lives.
Innovation Spotlight
POCTRN 2025 Innovation Award Opportunity
Innovation Spotlight
Webinar - RADx® Initiative & COVID-19 Solutions: Bioengineering at Unprecedented Speed and Scale
The webinar will discuss the RADx® Initiative, which was launched in April 2020 by the National Institutes of Health (NIH) to speed innovation in COVID-19 testing. The initiative has been incredibly successful in supporting the development and implementation of accurate, easy-to-use, and accessible testing technologies, and it serves as a useful model for current and future public-private partnerships and interagency collaboration.
Moderator:
Christine Parthemore, Chief Executive Officer, The Council on Strategic Risks
Speakers:
Dr. Bruce Tromberg, Director, NIBIB
Dr. Jill Heemskerk, Deputy Director, NIBIB
Dr. Rachel Fleurence, Senior Advisor to the Director, NIHWhen: June 8, 2022, 1:00-2:00PM ET
This webinar has passed.